111 related articles for article (PubMed ID: 32790249)
41. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
42. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
43. ENT-MS-12 questionnaire: A novel tool to investigate otolaryngology symptoms in patients with relapsing-remitting multiple sclerosis. Results from a pilot study.
Di Stadio A; Ralli M; Altieri M; Brenner MJ; Dipietro L; Messineo D; Kaski D; Bernitsas E
Mult Scler Relat Disord; 2021 Jan; 47():102660. PubMed ID: 33291034
[TBL] [Abstract][Full Text] [Related]
44. Iron deposition in the gray matter in patients with relapse-remitting multiple sclerosis: A longitudinal study using three-dimensional (3D)-enhanced T2*-weighted angiography (ESWAN).
Du S; Sah SK; Zeng C; Wang J; Liu Y; Xiong H; Li Y
Eur J Radiol; 2015 Jul; 84(7):1325-32. PubMed ID: 25959392
[TBL] [Abstract][Full Text] [Related]
45. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
46. Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing-remitting multiple sclerosis: an MRI cluster analysis study.
Barone S; Caligiuri ME; Valentino P; Cherubini A; Chiriaco C; Granata A; Filippelli E; Tallarico T; Nisticò R; Quattrone A
J Neurol; 2018 Oct; 265(10):2243-2250. PubMed ID: 30051273
[TBL] [Abstract][Full Text] [Related]
47. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
48. Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases.
Findling O; Rust H; Yaldizli Ö; Timmermans DPH; Scheltinga A; Allum JHJ
Front Neurol; 2018; 9():686. PubMed ID: 30186223
[No Abstract] [Full Text] [Related]
49. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
51. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
[TBL] [Abstract][Full Text] [Related]
52. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
[TBL] [Abstract][Full Text] [Related]
53. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
[TBL] [Abstract][Full Text] [Related]
54. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
55. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
[TBL] [Abstract][Full Text] [Related]
56. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
57. The Use of Breast Magnetic Resonance Imaging Parameters to Identify Possible Signaling Pathways of a Serum Biomarker, HE4.
Durur-Karakaya A; Durur-Subasi I; Karaman A; Akcay MN; Palabiyik SS; Erdemci B; Alper F; Acemoglu H
J Comput Assist Tomogr; 2016; 40(3):436-41. PubMed ID: 27192502
[TBL] [Abstract][Full Text] [Related]
58. Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis.
Doche E; Lecocq A; Maarouf A; Duhamel G; Soulier E; Confort-Gouny S; Rico A; Guye M; Audoin B; Pelletier J; Ranjeva JP; Zaaraoui W
J Neuroradiol; 2017 Mar; 44(2):158-164. PubMed ID: 27865557
[TBL] [Abstract][Full Text] [Related]
59. The effectiveness of fingolimod in a Portuguese real-world population.
Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
[TBL] [Abstract][Full Text] [Related]
60. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
